Published in final edited form as:

Am J Surg. 2019 June ; 217(6): 1037–1041. doi:10.1016/j.amjsurg.2019.01.014.

Discrepancies between Conventional and Viscoelastic Assays in Identifying Trauma-Induced Coagulopathy

Joshua J. Sumislawski, MD^a, S. Ariane Christie, MD^b, Lucy Z. Kornblith, MD^b, Gregory R. Stettler, MD^a, Geoffrey R. Nunns, MD^a, Hunter B. Moore, MD, PhD^a, Ernest E. Moore, MD^a, Christopher C. Silliman, MD, PhD^c, Angela Sauaia, MD, PhD^a, Rachael A. Callcut, MD, MSPH^b, Mitchell Jay Cohen, MD^a

^aDepartment of Surgery, Denver Health Medical Center, University of Colorado, 777 Bannock Street, MC 0206, Denver, Colorado 80204

^bDepartment of Surgery, Zuckerberg San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, Ward 3A, San Francisco, California 94110

^cDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado, 13123 East 16th Avenue, Aurora, Colorado 80045

Abstract

Background: Trauma-induced coagulopathy can present as abnormalities in a conventional or viscoelastic coagulation assay or both. We hypothesized that patients with discordant coagulopathies reflect different clinical phenotypes.

Methods: Blood samples were collected prospectively from critically injured patients upon arrival at two urban Level I trauma centers. International normalized ratio (INR), partial thromboplastin time (PTT), thromboelastography (TEG), and coagulation factors were assayed.

Results: 278 patients (median ISS 17, mortality 26%) were coagulopathic: 20% with isolated abnormal INR and/or PTT (CONVENTIONAL), 49% with isolated abnormal TEG (VISCOELASTIC), and 31% with abnormal INR/PTT and TEG (BOTH). Compared with VISCOELASTIC, CONVENTIONAL and BOTH had higher ISS, lower GCS, larger base deficit, and decreased factor activities (all $p < 0.017$). They received more blood products and had more ICU/ventilation days (all $p < 0.017$). Mortality was higher in CONVENTIONAL (40%) and BOTH (49%) than VISCOELASTIC (6%, $p < 0.017$).

Conclusions: Although TEG-guided resuscitation improves survival after injury, INR and PTT identify coagulopathic patients with highest mortality regardless of TEG and likely represent distinct mechanisms independent of biochemical clot strength.

Corresponding Author: Joshua J. Sumislawski, MD, Department of Surgery, Denver Health Medical Center, 777 Bannock Street, MC 0206, Denver, Colorado 80204, (303) 602-1830 (phone), (303) 436-6572 (fax), joshua.sumislawski@ucdenver.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Presentation History This study was presented at the 70th annual meeting of the Southwestern Surgical Congress; April 8–11, 2018; in Napa, California.

SUMMARY

Only 31% of patients with trauma-induced coagulopathy present with abnormalities in both conventional and viscoelastic coagulation assays. Although thromboelastography (TEG) has been shown to improve survival when used to guide resuscitation after injury, international normalized ratio and partial thromboplastin time identify coagulopathic patients with highest mortality regardless of TEG and reflect coagulation factor deficiencies.

Keywords

Trauma-induced coagulopathy; Thromboelastography; Resuscitation; Transfusion; Precision medicine

INTRODUCTION

Trauma-induced coagulopathy (TIC) occurs in one-third of severely injured patients and is associated with increased bleeding, morbidity, and mortality.^{1–3} Unlike congenital hematologic disorders, which often result from isolated abnormalities in the clotting system, TIC reflects a multifactorial biologic response initiated by tissue injury and shock and mediated by numerous mechanisms including coagulation factor depletion, protein C activation and depletion, fibrinolysis, and platelet and endothelial dysfunction.^{4–10}

When it was first recognized that trauma patients can present with coagulopathy prior to resuscitation, TIC was defined as prolongation of either international normalized ratio (INR) or partial thromboplastin time (PTT).^{1,2} Over the last decade, the use of viscoelastic hemostatic assays like thromboelastography (TEG) has increased in trauma because of their ability to identify specific clotting deficits underlying TIC and guide targeted treatment of these deficits.^{11–14} However, patients can arrive with an abnormality in either a conventional or viscoelastic test but not both, suggesting a discordance of unknown biochemical and clinical significance. These discordances might exist because of the multifactorial etiology of TIC and represent an important avenue of scientific investigation to facilitate individualized approaches to its diagnosis and treatment.¹⁵

Although the significance of discordant abnormalities between conventional coagulation tests like INR and PTT has previously been examined,¹⁶ discrepancies between conventional and viscoelastic tests remain poorly understood. The purpose of this prospective study was to identify injury and coagulation factor characteristics associated with differences between conventional and viscoelastic tests and to determine the outcomes associated with such discrepancies. We hypothesized that patients with discordant coagulopathies (isolated abnormal INR/PTT and isolated abnormal TEG) reflect distinct clinical phenotypes that provide prognostic and mechanistic insight into TIC.

METHODS

Arrival blood samples were collected prospectively from patients meeting criteria for highest-level trauma activation at two urban Level I trauma centers: Denver Health Medical Center in Denver, Colorado, and Zuckerberg San Francisco General Hospital in San

Francisco, California. Patients were excluded if they were <18-years-old, pregnant, incarcerated, transferred from another hospital, or taking outpatient anticoagulant or antiplatelet medications. Samples were obtained under protocols approved by the institutional review board for each center.

Our procedures for sample collection and analysis at each center have previously been described.^{14,17} In addition to conventional coagulation tests including INR and PTT, rapid TEG was performed on each sample following recalcification using a TEG® 5000 Thrombelastograph® Hemostasis Analyzer (Haemonetics Corporation; Braintree, Massachusetts). Parameters measured by TEG included activated clotting time (ACT, the time from the start of the test to initial clot formation), alpha angle (α ; the slope of the tracing, which represents the rate of clot formation), and maximum amplitude (MA; the greatest amplitude of the tracing, which illustrates clot strength). Samples were also assayed for coagulation factors II, V, VII, VIII, IX, and X; protein C; D-dimer; and antithrombin III using a STA Compact Max® (Diagnostica Stago; Parsippany, New Jersey).

TIC was classified into three phenotypes using the results of INR, PTT, and TEG (Table 1). Patients with isolated abnormal INR and/or PTT (INR ≥ 1.4 and/or PTT ≥ 35 s) but normal TEG were designated CONVENTIONAL. Those with isolated abnormal TEG (ACT ≥ 128 s, angle $<65^\circ$, and/or MA <55 mm) but normal INR/PTT were designated VISCOELASTIC.¹⁴ Those with abnormalities in both a conventional and viscoelastic test were designated BOTH. Patients were considered noncoagulopathic if their INR was <1.4 , PTT <35 s, ACT <128 s, angle $\geq 65^\circ$, and MA ≥ 55 mm.

Demographic, injury, resuscitation, and outcome data were collected for all patients. Summary statistics are reported as mean with standard deviation for normally distributed data, median with interquartile range for skewed data, and percentage for binary data. Univariate differences between groups were evaluated using Student's *t*-test or one-way analysis of variance (ANOVA) for normally distributed data, Wilcoxon rank-sum or Kruskal-Wallis tests for skewed data, and Fisher's exact test for binary data. Multinomial logistic regression was performed following a stepwise selection procedure to identify independent predictors of discordant coagulopathies while controlling for significant covariates. Kaplan-Meier curves were generated to compare survival times by coagulopathic phenotype. A *p*-value <0.05 was considered significant, except when adjusted for multiple comparisons with Bonferroni correction. Statistical analyses were performed with Stata/SE 15 (StataCorp; College Station, Texas).

RESULTS

Study Population

From December 2010 to June 2017, 839 patients were enrolled. These patients were mostly male (81%) and young [median age 33 y (IQR 25–47)], representing a typical trauma population. They had a median Injury Severity Score (ISS) of 10 (IQR 2–26) and median base deficit of 5.0 (IQR 1.0–9.1). 51% sustained blunt trauma, and the entire cohort received minimal intravenous fluid prior to sample collection [median 100 mL (IQR 0–350)].

Coagulopathic versus Noncoagulopathic Patients

278 patients (33%) arrived with coagulopathy by at least one conventional or viscoelastic parameter (Table 2). Consistent with previous studies on TIC, these patients were more severely injured than noncoagulopathic patients (ISS 17 vs 10, $p<0.001$) and presented with a larger base deficit (7.0 vs 4.0, $p<0.001$). Coagulopathic patients required more blood transfusions within the first 24 hours and experienced more intensive care unit (ICU) and ventilator days. Mortality was higher for coagulopathic patients (26%) than for noncoagulopathic patients (4%, $p<0.001$).

Coagulopathic Phenotypes

Among coagulopathic patients, 55 (20%) had isolated abnormal INR/PTT (CONVENTIONAL), 137 (49%) isolated abnormal TEG (VISCOELASTIC), and 86 (31%) abnormal INR/PTT and TEG (BOTH). The characteristics of these coagulopathic phenotypes are depicted in Table 3. Compared with VISCOELASTIC, patients with abnormal INR/PTT (CONVENTIONAL and BOTH) were more severely injured, especially with intracranial injuries as demonstrated by their higher head Abbreviated Injury Scale (AIS) and lower Glasgow Coma Scale (GCS) scores (all $p<0.017$ for multiple comparisons). Likewise, they were more acidotic with greater base deficit (all $p<0.017$).

Factor activities differed significantly among the coagulopathic phenotypes (Table 3 and Figure 1). Compared with VISCOELASTIC, patients with abnormal INR/PTT (CONVENTIONAL and BOTH) had decreased activities of factors in the tissue factor (VII), contact (IX), and common (X, V, and II) coagulation pathways (all $p<0.017$). Factor VIII activity was not different among groups. In addition, CONVENTIONAL and BOTH were associated with lower fibrinogen, higher D-dimer, and lower antithrombin III activity than VISCOELASTIC (Table 3, all $p<0.017$).

Resuscitation requirements and outcomes differed among the three coagulopathic phenotypes (Table 3). CONVENTIONAL and BOTH received more blood transfusions during the first 24 hours and had more ICU and ventilator days (all $p<0.017$). Overall mortality was higher for CONVENTIONAL (40%) and BOTH (49%) than VISCOELASTIC (6%, $p<0.001$). This latter finding was consistent with Kaplan-Meier survival analysis (Figure 2).

Discordant Coagulopathies

After adjusting for significant covariates, ISS and factor II (a common pathway factor) were the only independent predictors of discordance (Table 4).

DISCUSSION

In the current prospective observational study, we identified the characteristics of patients with discrepancies between conventional and viscoelastic tests. Coagulopathic patients with abnormal INR/PTT, regardless of the results of their TEG, were more severely injured with more profound shock, required more blood transfusions, and experienced higher mortality than those with normal INR/PTT but abnormal TEG. Most interestingly, these patients

(CONVENTIONAL and BOTH) had lower activity levels for all coagulation factors except VIII. Multinomial logistic regression analysis, which controlled for age, sex, injury severity, and shock, identified factor II as an independent predictor of discordance between conventional and viscoelastic tests. Because factor II contributes to the common coagulation pathway, these findings suggest that patients with elevated INR and/or PTT but normal TEG should continue to be resuscitated aggressively with blood products to replete these factor deficiencies.¹⁸ Conventional coagulation tests remain an important indicator of coagulopathy after trauma and should continue to be obtained with initial trauma labs.

When first recognized as a direct sequela of tissue injury and shock, TIC was described as a prolongation of either PTT or prothrombin time, which had been designed to monitor anticoagulant therapy.^{1,2} Upon arrival at a trauma center, abnormalities of these tests portended increased bleeding, morbidity, and mortality.¹⁻³ Although this finding challenged the notion at the time that post-injury coagulopathy resulted iatrogenically from resuscitation, it did not identify specific clotting deficits that could be targeted to treat TIC. Consequently, patients were resuscitated empirically with fixed ratios of blood products.^{19,20}

As we progress into an era of precision medicine, much work has been done to individualize treatment of TIC.^{11-16,21-23} Critical to these efforts has been the increased use of viscoelastic hemostatic assays, which assess whole-blood clot formation and degradation and can identify specific coagulation deficits for targeted treatment with blood products or hemostatic adjuncts.¹¹⁻¹⁴ Our group previously conducted a prospective, randomized trial which demonstrated that viscoelastic assays improve survival compared with conventional tests when used to guide resuscitation.¹³ Nevertheless, discrepancies between these two types of tests exist and can create a management dilemma for clinicians.

Although this study supports the need for combined use of conventional and viscoelastic assays, viscoelastic assays should still play the primary role in guiding resuscitation, as they have been shown to be superior to conventional tests for this purpose.¹³ Furthermore, while conventional tests identify coagulopathy, viscoelastic assays supply mechanistic details that facilitate targeted treatment of a specific derangement. In addition, they are superior in their ability to identify hypercoagulability and quantify clot degradation by percent lysis.²⁴ Most importantly, TEG can be performed rapidly, with ACT available in five minutes. While this feature allows early identification and treatment of TIC, certain coagulopathic patients can be missed by TEG, as suggested in this study. This finding highlights the need for a test that promptly identifies patients with greatest need for transfusion, as INR and PTT do, and can guide targeted treatment of these patients, as TEG does.

We recognize several limitations of this study beyond those inherent in its prospective observational design. While conducting this study at two institutions provided adequate patient numbers, transfusion practices were not identical at each center and inevitably varied among providers. Specifically, resuscitation is guided by TEG in Denver but not San Francisco. Likewise, the thresholds used to define coagulopathy by INR, PTT, and TEG are not absolute and were developed for different purposes. Elevated INR and PTT are associated with increased mortality, while TEG thresholds have previously been chosen based on the need for massive transfusion.¹⁴ It is also important to note that the TEG

parameter percent lysis at 30 minutes (LY30) was not included in this analysis because there is no corollary conventional test that quantifies clot degradation.

This study represents an important attempt to describe discrepancies between conventional and viscoelastic assays in identifying TIC, and while it suggests that such discrepancies reflect differences in coagulation factor activities, future studies are needed to clarify the utility of this finding. Specifically, subsequent studies should address whether correction of lower factor activity levels with transfusions improves survival. Although the phenotypic characters of patients with abnormal INR versus PTT have already been addressed in prior work from our group, the individual contributions of each TEG parameter to coagulopathy and patient outcomes should be addressed.

CONCLUSIONS

Only 31% of patients with TIC present with an abnormality in both conventional and viscoelastic hemostatic assays. Although TEG-guided resuscitation has been shown to improve survival after injury, INR and PTT identify coagulopathic patients with highest mortality regardless of TEG and likely represent distinct mechanisms independent of biochemical clot strength. Specifically, elevated INR and PTT reflect decreased coagulation factor activities, suggesting that factor repletion might be the appropriate therapy for patients who present with these abnormalities but normal TEG.

Funding

This study was supported by the National Institutes of Health (grants UM1HL120877 to MJC; K01ES026834 to RAC; and T32GM08315 to GRS, GRN, and HBM) and the United States Department of Defense (contract W911QY-15-C-0044 to MJC and RAC).

REFERENCES

1. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *J Trauma*. 2003;54:1127–30. [PubMed: 12813333]
2. MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. *J Trauma*. 2003;55:39–44. [PubMed: 12855879]
3. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. *J Trauma*. 2008;64:1459–63. [PubMed: 18545109]
4. Shaz BH, Winkler AM, James AB, et al. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. *J Trauma*. 2011;70:1401–7. [PubMed: 21460741]
5. Kunitake RC, Howard BM, Kornblith LZ, et al. Individual clotting factor contributions to mortality following trauma. *J Trauma Acute Care Surg*. 2017;82:302–8. [PubMed: 27906868]
6. Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. *Ann Surg*. 2012;255:379–85. [PubMed: 22133894]
7. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. *Ann Surg*. 2010;252:434–44. [PubMed: 20739843]
8. Kutcher ME, Redick BJ, McCreery RC, et al. Characterization of platelet dysfunction after trauma. *J Trauma Acute Care Surg*. 2012;73:13–9. [PubMed: 22743367]
9. Kutcher ME, Ferguson AR, Cohen MJ. A principal component analysis of coagulation after trauma. *J Trauma Acute Care Surg*. 2013;74:1223–30. [PubMed: 23609271]

10. Cohen MJ, Kutcher M, Redick B, et al. Clinical and mechanistic drivers of acute traumatic coagulopathy. *J Trauma Acute Care Surg.* 2013;75:S40–7. [PubMed: 23778510]
11. Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. *Ann Surg.* 2010;251:604–14. [PubMed: 20224372]
12. Cotton BA, Faz G, Hatch QM, et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. *J Trauma.* 2011;71:407–7. [PubMed: 21825945]
13. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. *Ann Surg.* 2016;263:1051–9. [PubMed: 26720428]
14. Einersen PM, Moore EE, Chapman MP, et al. Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion. *J Trauma Acute Care Surg.* 2017;82:114–9. [PubMed: 27805995]
15. Cohen MJ. Translational approaches to coagulopathy after trauma: towards targeted treatment. *PLoS Med.* 2017;14(7).
16. Christie SA, Kornblith LZ, Howard BM, et al. Characterization of distinct coagulopathic phenotypes in injury: pathway-specific drivers and implications for individualized treatment. *J Trauma Acute Care Surg.* 2017;82:1055–62. [PubMed: 28338598]
17. Kornblith LZ, Howard B, Kunitake R, et al. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury. *J Trauma Acute Care Surg.* 2015;78:30–8. [PubMed: 25539200]
18. Ho AM, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major trauma resuscitation? *Am J Surg.* 2005;190:479–84. [PubMed: 16105540]
19. Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. *J Trauma.* 2009;66:41–9. [PubMed: 19131804]
20. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA.* 2015;313:471–82. [PubMed: 25647203]
21. Díaz I, Hubbard A, Decker A, et al. Variable importance and prediction methods for longitudinal problems with missing variables. *PLoS One.* 2015;10.
22. Moore SE, Decker A, Hubbard A, et al. Statistical machines for trauma hospital outcomes research: application to the PROspective, Observational, Multi-Center Major Trauma Transfusion (PROMMTT) study. *PLoS One.* 2015;10.
23. Menezes AA, Vilardi RF, Arkin AP, et al. Targeted clinical control of trauma patient coagulation through a thrombin dynamics model. *Sci Transl Med.* 2017;9.
24. Park MS, Martini WZ, Dubick MA, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. *J Trauma.* 2009;67:266–76. [PubMed: 19667878]

HIGHLIGHTS

31% of patients with TIC have both abnormal conventional and viscoelastic assays.

Conventional assays identify more severely injured patients than viscoelastic.

Abnormal conventional assays are associated with higher mortality.

Abnormal conventional assays might reflect coagulation factor deficiencies.

FIGURE 1.
Coagulation factor activities by coagulopathic phenotype.

FIGURE 2.
Kaplan-Meier survival analysis by coagulopathic phenotype.

TABLE 1.

Coagulopathic Phenotypes.

CONVENTIONAL		VISCOELASTIC		BOTH	
•	INR 1.4 and/or PTT 35 s	•	ACT >128 s, angle <65°, and/or MA <55 mm	•	Abnormal INR/PTT
•	Normal TEG	•	Normal INR/PTT	•	Abnormal TEG

ACT, activated clotting time; INR, international normalized ratio; MA, maximum amplitude; PTT, partial thromboplastin time; TEG, thromboelastography.

TABLE 2.

Characteristics of Coagulopathic versus Noncoagulopathic Patients.

	Noncoagulopathic (n=561)	Coagulopathic (n=278)	<i>p</i>
Age (y)	34 (26, 47)	31 (24, 46)	0.050
Male	81%	82%	0.641
BMI (kg/m ²)	26.6 (23.3, 30.5)	25.4 (23.0, 29.0)	0.029
Blunt mechanism	47%	59%	0.002
ISS	10 (2, 22)	17 (5, 34)	<0.001
Head AIS score	0 (0, 2)	0 (0, 4)	<0.001
GCS score	15 (12, 15)	11 (3, 15)	<0.001
Platelet count ($\times 10^9/L$)	273 (233, 322)	221 (171, 289)	<0.001
Fibrinogen (mg/dL)	237 (186, 295)	174 (137, 232)	<0.001
D-dimer ($\mu g/mL$)	0.8 (0.3, 4.0)	3.7 (0.7, 8.9)	<0.001
pH	7.34 (7.27, 7.39)	7.28 (7.16, 7.37)	<0.001
Base deficit	4.0 (0.4, 7.9)	7.0 (3.0, 12.8)	<0.001
Lactate (mg/dL)	3.2 (2.3, 5.0)	4.7 (2.8, 8.6)	<0.001
Factor II (% activity)	77 (63, 91)	68 (51, 81)	<0.001
Factor V (% activity)	54 (36, 71)	43 (24, 69)	0.003
Factor VII (% activity)	83 (62, 105)	72 (51, 89)	<0.001
Factor VIII (% activity)	159 (95, 253)	177 (93, 277)	0.505
Factor IX (% activity)	123 (104, 153)	107 (77, 136)	<0.001
Factor X (% activity)	82 (65, 98)	72 (54, 85)	<0.001
ATIII (% activity)	89 (71, 107)	73 (50, 98)	<0.001
Protein C (% activity)	93 (± 28)	76 (± 31)	0.149
Crystalloid, first 24 h (mL)	3500 (1502, 5779)	4130 (2301, 7082)	<0.001
RBC, first 24 h (u)	0 (0, 1)	2 (0, 7)	<0.001
Plasma, first 24 h (u)	0 (0, 0)	2 (0, 6)	<0.001
Platelets, first 24 h (u)	0 (0, 0)	0 (0, 1)	<0.001
Hospital LOS (d)	5 (2, 13)	5 (2, 14)	0.528
ICU LOS (d)	2 (0, 5)	2 (0, 7)	0.001
Ventilation days	0 (0, 2)	2 (0, 4)	<0.001
Mortality	4%	26%	<0.001

AIS, Abbreviated Injury Scale; ATIII, antithrombin III; BMI, body mass index; GCS, Glasgow Coma Scale; ICU, intensive care unit; ISS, Injury Severity Score; LOS, length of stay; RBC, red blood cells.

TABLE 3.

Characteristics of Patients by Coagulopathic Phenotype.

	CONVENTIONAL (n=55)	VISCOELASTIC (n=137)	BOTH (n=86)	<i>p</i>
Age (y)	33 (24, 49)	32 (25, 45)	30 (23, 44)	0.511
Male	75%	85%	81%	0.209
BMI (kg/m ²)	26.3 (22.6, 30.1)	25.1 (22.9, 29.0)	25.4 (23.9, 28.4)	0.722
Blunt mechanism	69%	53%	60%	0.123
ISS	27 (9, 38)	9 (1, 20)	34 (26, 43)	<0.001
Head AIS score	3 (0, 5)	0 (0, 3)	3 (0, 5)	<0.001
GCS score	6 (3, 15)	14 (10, 15)	3 (3, 13)	<0.001
Prehospital crystalloid (mL)	150 (0, 400)	100 (0, 300)	200 (0, 500)	0.079
Platelets ($\times 10^9/L$)	227 (179, 305)	231 (193, 299)	179 (123, 261)	<0.001
Fibrinogen (mg/dL)	161 (141, 191)	214 (169, 274)	134 (106, 173)	<0.001
D-dimer ($\mu g/mL$)	5.1 (1.3, 9.4)	0.8 (0.3, 4.7)	8.2 (3.6, 15.4)	<0.001
pH	7.22 (7.08, 7.32)	7.34 (7.26, 7.38)	7.18 (7.05, 7.33)	<0.001
Base deficit	7.6 (2.8, 13.0)	4.8 (1.7, 9.0)	10.8 (4.5, 17.2)	<0.001
Lactate (mg/dL)	4.4 (2.7, 8.5)	4.1 (2.6, 5.5)	7.9 (3.9, 12.3)	<0.001
Factor II (% activity)	57 (40, 72)	73 (63, 84)	59 (46, 70)	<0.001
Factor V (% activity)	30 (21, 47)	61 (41, 76)	23 (17, 40)	<0.001
Factor VII (% activity)	58 (45, 79)	79 (62, 96)	55 (43, 87)	0.009
Factor VIII (% activity)	111 (71, 226)	186 (141, 322)	177 (74, 289)	0.054
Factor IX (% activity)	75 (66, 129)	132 (103, 153)	86 (55, 113)	<0.001
Factor X (% activity)	68 (42, 79)	78 (67, 92)	58 (52, 77)	0.002
ATIII (% activity)	56 (30, 87)	82 (68, 101)	57 (37, 80)	0.002
Protein C (% activity)	64 (± 28)	87 (± 30)	61 (± 30)	0.962
Crystalloid, first 24 h (mL)	5238 (3000, 7926)	3043 (2000, 5200)	5873 (2700, 9814)	<0.001
RBC, first 24 h (u)	2 (0, 6)	0 (0, 2)	7 (3, 22)	<0.001
Plasma, first 24 h (u)	2 (0, 8)	0 (0, 2)	5 (3, 14)	<0.001
Platelets, first 24 h (u)	0 (0, 1)	0 (0, 0)	1 (0, 2)	<0.001
Hospital LOS (d)	6 (2, 20)	4 (2, 10)	5 (1, 19)	0.153
ICU LOS (d)	3 (2, 9)	2 (0, 5)	3 (1, 13)	0.007
Ventilation days	2 (1, 5)	1 (0, 3)	2 (1, 10)	<0.001
Mortality	40%	6%	49%	<0.001

AIS, Abbreviated Injury Scale; ATIII, antithrombin III; BMI, body mass index; GCS, Glasgow ComaScale; ICU, intensive care unit; ISS, Injury Severity Score; LOS, length of stay; RBC, red blood cells.

TABLE 4.

Predictors of Discordant Coagulopathies.

	Phenotype	OR (95% CI)	<i>p</i>
ISS	CONVENTIONAL	1.073 (1.019, 1.129)	0.007
	VISCOELASTIC	Reference	—
	BOTH	1.104 (1.042, 1.169)	<0.001
Factor II	CONVENTIONAL	0.953 (0.916, 0.990)	0.014
	VISCOELASTIC	Reference	—
	BOTH	0.950 (0.908, 0.993)	0.024

Model performance was assessed using deviance ($p=0.975$) and Pearson's chi-squared test ($p=0.081$), for both of which higher p indicates a better fit. CI, confidence interval; ISS, Injury Severity Score; OR, odds ratio.